PDF, Patent Landscape Report on Atazanavir - WIPO

collection for nuggets of intelligence. It separates the activity of the developer of Atazanavir(Novartis and its licensee Bristol-Myers Squibb) from activity of other entities, andcompares the two across a timeline. It identifies the inventions that reference standardphases of drug development including: composition discovery, establishing biologicaltargets (pathway modulation effects), developing synthetic methods, formulating fortreatment, describing best disease indications, investigating combinations, improvingsynthesis, and broadening uses. While there is a very rough linear relationship betweenthem, new information developed either by the developer or externally can trigger iterationsin developmental steps that break down any simple linear picture.Because combination therapies involving more than one drug are such an integral part ofpharmaceutical development, and because that is especially true for AIDS therapies, aseparate chapter of the report will focus on combinations.This report provides an integrated narrative that, at each step, draws attention to how thedata elements satisfy the objectives, and explicitly points out the reasoning that allowsinferences to be made.Last, the report presents greater detail on use of various types of indexing and post-filingadditions to the patent information.The <strong>Report</strong> Appendices include specific search strategies, a file containing bibliographicinformation on the collection and links to the documents, and clinical trials information.5